Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?

Author:

Gravara Luigi Della1,Battiloro Ciro2,Cantile Rosa2,Letizia Antonietta2,Vitiello Fabiana2,Montesarchio Vincenzo3,Rocco Danilo2ORCID

Affiliation:

1. Department of Experimental Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Caserta, Italy

2. Division of Pulmonary Oncology, AORN dei Colli Monaldi, Naples, Italy

3. Division of Medical Oncology, AORN dei Colli Monaldi, Naples, Italy

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Immuno-Oncology: Emerging Targets and Combination Therapies

2. The role of combination chemo-immunotherapy in advanced non-small cell lung cancer

3. US FDA. FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC (2018). www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617471.htm

4. Merck & Co., Inc. European commission approves Merck's KEYTRUDA® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations (2018). https://investors.merck.com/news/press-release-details/2018/European-Commission-Approves-Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pemetrexed-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-Patients-with-Metastatic-Nonsquamous-NSCLC-with-No-EGFR-or-ALK-Genomic-Tumor-Aberrations/default.aspx

5. US FDA. FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC (2018). www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm624659.htm

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3